| Filed On | Filing |
|---|---|
| 12 Aug 2026 |
Form 4: Pauls Dietrich John, Director
Received 60,200 shares as a grant or award |
| 11 Aug 2026 | FORM S-8 |
| 10 Aug 2026 | FORM 10-Q |
| 10 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 03 Jun 2026 |
Form 4: Giuffre Randall Michael, Director
Granted 40,412 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Kuntz Richard, Director
Granted 40,412 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: O'Connor Daniel J., Director
Granted 40,412 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Lewis Tanya, Director
Granted 40,412 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Semba Charles Pauling, Director
Granted 40,412 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Parsons James T., Director
Granted 51,189 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Pauls Dietrich John, Director
Granted 380,000 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Kellen Scott, CFO & Secretary
Granted 162,000 Stock Option (right to buy) |
| 03 Jun 2026 |
Form 4: Krop Julie, Chief Medical Officer
Granted 67,500 Stock Option (right to buy) |
| 21 May 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 06 May 2026 | FORM 10-Q |
| 06 May 2026 | 8-K: Results of Operations and Financial Condition |
| 01 Apr 2026 | ARS |
| 01 Apr 2026 | FORM DEFA14A |
| 01 Apr 2026 |
Proxy statement: annual meeting on May 20, 2026
CEO pay $2.7M, up 76% · say-on-pay vote |
| 31 Mar 2026 | 8-K: Results of Operations and Financial Condition |
Loading...
